Oric chases Pfizer into phase 3 hailing prostate cancer edge, but investors send stock down
Fuente:
FierceBiotech
Oric Pharmaceuticals has picked the phase 3 dose for its prostate cancer prospect, barreling into the pivotal program while outlining a claimed edge over Pfizer’s rival candidate.